Gerresheimer AG: Gerresheimer enters into agreement with major American biotech to develop an innovative pump for rare diseases
Düsseldorf, December 16, 2021 - Gerresheimer has entered into an important agreement involving its Advanced Technologies division. An established US biotech company will rely on Gerresheimer's innovative strength and engineering expertise for the development of a new pump to deliver a leading drug for the treatment of rare diseases via continuous parenteral administration.
"This agreement is another important milestone on our way to becoming a solution provider for leading and innovative medical devices." said Dietmar Siemssen, CEO of Gerresheimer AG. "Our patented pump technology has already proven itself in use for Parkinson's therapy and in future we expect it will also help to improve the quality of life of people with rare diseases. Our broad portfolio for the pharma and biotech industry makes it possible to develop the best solution together with our customers and implement it with a perfect fit."
The exclusive agreement between Gerresheimer and the American biotech addresses the regions USA and Canada, with a right of first refusal granted to the partner to cover additional territories. Gerresheimer therefore plans to have a pump approved by the United States Food and Drug Administration in the future.
The innovative pump consists of two parts, one of which can be reused, thus increasing the sustainability of the solution. At its core is the already patented SenseCore technology.
Contact Investor Relations
End of Media Release
Issuer: Gerresheimer AG
Key word(s): Enterprise
16.12.2021 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1258818|
|End of News||DGAP Media|